Add Yahoo as a preferred source to see more of our stories on Google. ON THIS PAGE Treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) includes IV infusion at a medical clinic, but ...

A review in Discover Pharmaceutical Sciences details how large-volume subcutaneous delivery is transforming drug ...

BACKGROUND: Current prescribing information recommends that physicians apply a dose ratio of 1.37:1 (1.53:1 prior to January 2015) in the United States (US) when switching patients with primary ...

For people living with primary immunodeficiency (PI), immunoglobulin replacement therapy (Ig) is a cornerstone of treatment. It helps prevent serious infections, reduces hospitalizations, and supports ...

New York, NY, Jan. 29, 2024 (GLOBE NEWSWIRE) -- A latest research report [115+] pages with 360-degree visibility, titled "Subcutaneous Immunoglobulin Market Share, Size, Trends, Industry Analysis ...

Results from the PATH study indicate that subcutaneous immunoglobulin is efficacious and well tolerated for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). This ...

SAN DIEGO — Patients with multiple myeloma who receive intravenous immunoglobulin (IVIG) prophylaxis during treatment with teclistamab have fewer infections and better overall survival compared with ...

Treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) includes IV infusion at a medical clinic, but now you can get a similar treatment through an injection or infusion at home.